Regulatory approval

Published by the European Medicines Agency. Approved

Etcamah in combination with a CDK4/6 inhibitor (palbociclib, ribociclib, or abemaciclib) is indicated for the treatment of adult patients with ER-positive, HER2-negative, locally advanced or metastatic breast cancer upon detection of ESR1-mutation and without disease progression during first-line endocrine therapy in combination with a CDK4/6 inhibitor.

This is written in the approval document.

Citation

AstraZeneca AB. Etcamah (camizestrant) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/etcamah-epar-product-information_en.pdf. Revised July 2026. Accessed August 2, 2026.

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies
EMA (1)	ER positive, ESR1 activating variants, HER2-negative	Invasive Breast Carcinoma	Abemaciclib, Camizestrant
EMA (1)	ER positive, ESR1 activating variants, HER2-negative	Invasive Breast Carcinoma	Camizestrant, Palbociclib
EMA (1)	ER positive, ESR1 activating variants, HER2-negative	Invasive Breast Carcinoma	Camizestrant, Ribociclib

Contributions

Date	Contributor	Description
2026-08-02	Van Allen lab	Initial curation of into moalmanac-db
2026-07-20	European Medicines Agency	Indication received approval from the European Commission.